10547391

Source:http://linkedlifedata.com/resource/pubmed/id/10547391

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006141, umls-concept:C0006142, umls-concept:C0006826, umls-concept:C0008976, umls-concept:C0034656, umls-concept:C0043210, umls-concept:C0060197
pubmed:issue	21
pubmed:dateCreated	1999-11-30
pubmed:abstractText	Fenretinide, a vitamin A analogue, has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of fenretinide in preventing a second breast malignancy in women with breast cancer.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA38567, http://linkedlifedata.com/resource/pubmed/grant/CA72286
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/10547391-10547379, http://linkedlifedata.com/resource/pubmed/commentcorrection/10547391-10655447, http://linkedlifedata.com/resource/pubmed/commentcorrection/10547391-10655448, http://linkedlifedata.com/resource/pubmed/commentcorrection/10547391-11158198
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503089
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Fenretinide, http://linkedlifedata.com/resource/pubmed/chemical/Vitamin A
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0027-8874
pubmed:author	pubmed-author:BondHH, pubmed-author:CameriniTT, pubmed-author:CampsFF, pubmed-author:CostaAA, pubmed-author:D'AiutoGG, pubmed-author:De PaloGG, pubmed-author:DecensiAA, pubmed-author:Del TurcoM RMR, pubmed-author:Del VecchioMM, pubmed-author:Di MauroM GMG, pubmed-author:FormelliFF, pubmed-author:MagniAA, pubmed-author:MaloneW FWF, pubmed-author:MarianiLL, pubmed-author:MarubiniEE, pubmed-author:MiceliRR, pubmed-author:MuracaM GMG, pubmed-author:PerloffMM, pubmed-author:PintoCC, pubmed-author:SpornM BMB, pubmed-author:VeronesiUU
pubmed:issnType	Print
pubmed:day	3
pubmed:volume	91
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1847-56
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:10547391-Adult, pubmed-meshheading:10547391-Aged, pubmed-meshheading:10547391-Anticarcinogenic Agents, pubmed-meshheading:10547391-Antineoplastic Agents, pubmed-meshheading:10547391-Breast Neoplasms, pubmed-meshheading:10547391-Disease-Free Survival, pubmed-meshheading:10547391-Female, pubmed-meshheading:10547391-Fenretinide, pubmed-meshheading:10547391-Humans, pubmed-meshheading:10547391-Incidence, pubmed-meshheading:10547391-Middle Aged, pubmed-meshheading:10547391-Neoplasm Staging, pubmed-meshheading:10547391-Neoplasms, Second Primary, pubmed-meshheading:10547391-Proportional Hazards Models, pubmed-meshheading:10547391-Research Design, pubmed-meshheading:10547391-Risk, pubmed-meshheading:10547391-Risk Factors, pubmed-meshheading:10547391-Treatment Outcome, pubmed-meshheading:10547391-Vitamin A
pubmed:year	1999
pubmed:articleTitle	Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
pubmed:affiliation	U. Veronesi, A. Costa, A. Decensi, Istituto Europeo di Oncologia, Milan, Italy.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Clinical Trial, Phase III